Geode Capital Management LLC Purchases 21,262 Shares of INmune Bio, Inc. (NASDAQ:INMB)

Geode Capital Management LLC raised its position in INmune Bio, Inc. (NASDAQ:INMB) by 6.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 344,466 shares of the company’s stock after purchasing an additional 21,262 shares during the quarter. Geode Capital Management LLC owned 1.55% of INmune Bio worth $1,857,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. State Street Corp increased its stake in shares of INmune Bio by 35.1% in the third quarter. State Street Corp now owns 226,428 shares of the company’s stock valued at $1,220,000 after buying an additional 58,838 shares during the period. CVI Holdings LLC bought a new stake in INmune Bio during the 2nd quarter worth approximately $5,260,000. Rhumbline Advisers acquired a new position in INmune Bio in the 2nd quarter valued at approximately $121,000. Barclays PLC raised its stake in shares of INmune Bio by 601.9% during the third quarter. Barclays PLC now owns 29,044 shares of the company’s stock valued at $157,000 after acquiring an additional 24,906 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of INmune Bio during the third quarter valued at $249,000. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Stock Performance

Shares of NASDAQ INMB opened at $5.30 on Thursday. The company’s 50 day moving average price is $5.16 and its 200-day moving average price is $6.18. INmune Bio, Inc. has a 52-week low of $4.32 and a 52-week high of $14.74. The company has a market capitalization of $117.51 million, a P/E ratio of -2.43 and a beta of 1.78.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 117.48% and a negative net margin of 26,333.59%. During the same quarter in the prior year, the company posted ($0.48) EPS. Analysts forecast that INmune Bio, Inc. will post -2.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

INMB has been the subject of a number of recent research reports. Raymond James assumed coverage on INmune Bio in a report on Friday, September 27th. They issued an “outperform” rating and a $18.00 price objective for the company. Alliance Global Partners assumed coverage on INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 price target for the company.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.